An Official Website of the United States Government
Company Information:
Name:
Bearsden Bio, Inc.
Address:
34 MT PLEASANT DR
Frazer, PA 19014
Frazer, PA 19014
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
NOVEL TARGETS FOR CONTROL OF APP EXPRESSION
Award Year / Program / Phase:
1997 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Giordano, anthony
Award Amount:
$99,769.00
Abstract:
Alzheimer's disease is a major illness affecting an increasingly larger percentage of the population. As yet, the cause of the disease remains unknown, complicating the development of effective therapeutics. However, evidence continues to implicate the Abeta peptide, derived from the APP protein,… More
POSTTRANSCRIPTIONAL CONTROL OF IGF I RECEPTOR EXPRESSION
Award Year / Program / Phase:
1997 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Temeles, gretchen l
Award Amount:
$100,000.00
Abstract:
Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer death for men in the United States. Prostate tumor cells express high levels of the IGF-I receptor (IGF-IR) and because bone marrow is rich in the ligands, IGF-I and IGF-II, it has been proposed that a… More
AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EPILEPSY
Award Year / Program / Phase:
1997 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Sturgess, michael a
Award Amount:
$95,231.00
Abstract:
The development of novel compounds that regulate specific subtypes of glutamate receptors for the treatment of CNS disorders is the major goal of Symphony Pharmaceuticals, Inc. Symphony discovered a novel series of heterocyclic 1,2-dihydrophthalazines that selectively antagonize AMPA receptors and… More
MOLECULAR CLONING OF UNIQUE CYTOKINES & PROTOONCOGENES
Award Year / Program / Phase:
1997 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Giordano, anthony
Award Amount:
$100,000.00
Kainate Receptor Antagonists to Treat Neuropathis Pain
Award Year / Program / Phase:
1998 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Sturgess, michael a
Award Amount:
$744,554.00
Abstract:
The development of novel compounds that regulate specific subtypes of glutamate receptors for the treatment of CNS disorders is the major goal of Symphony Pharmaceuticals, Inc. Symphony discovered a novel series of heterocyclic 1,2-dihydrophthalazines that selectively antagonize AMPA receptors and… More
SITE DIRECTED PROTEIN ANALYSIS WITH NOVEL AMINO ACIDS
Award Year / Program / Phase:
1998 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Karginov, Vladimir
Award Amount:
$99,122.00
N/A
Award Year / Program / Phase:
1999 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Karginov Vladimir
Award Amount:
$811,363.00